journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Drug Safety

journal
https://www.readbyqxmd.com/read/29623187/moxifloxacin-induced-tinnitus-in-an-older-adult
#1
Amber Onoh, Sunny A Linnebur, Danielle R Fixen
An increased risk of bacterial resistance toward fluoroquinolones and the increased risk of disabling and serious adverse effects prompted the US Food and Drug Administration to recommend limiting fluoroquinolone use to the treatment of community-acquired pneumonia, skin and skin-structure infections, bacterial sinusitis, plague, chronic bronchitis exacerbations, and complicated intra-abdominal infections. We report a case of moxifloxacin-induced tinnitus in an older adult prescribed oral moxifloxacin 400 mg for 5 days for the treatment of acute diverticulitis, due to allergies to nonfluoroquinolone preferred agents...
April 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29623186/trigger-alerts-associated-with-laboratory-abnormalities-on-identifying-potentially-preventable-adverse-drug-events-in-the-intensive-care-unit-and-general-ward
#2
Mitchell S Buckley, Jeffrey R Rasmussen, Dale S Bikin, Emily C Richards, Andrew J Berry, Mark A Culver, Ryan M Rivosecchi, Sandra L Kane-Gill
Background: Medication safety strategies involving trigger alerts have demonstrated potential in identifying drug-related hazardous conditions (DRHCs) and preventing adverse drug events in hospitalized patients. However, trigger alert effectiveness between intensive care unit (ICU) and general ward patients remains unknown. The objective was to investigate trigger alert performance in accurately identifying DRHCs associated with laboratory abnormalities in ICU and non-ICU settings. Methods: This retrospective, observational study was conducted at a university hospital over a 1-year period involving 20 unique trigger alerts aimed at identifying possible drug-induced laboratory abnormalities...
April 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29623185/spontaneously-reported-adverse-drug-events-related-to-tapentadol-and-oxycodone-naloxone-in-australia
#3
Carmen Abeyaratne, Samanta Lalic, J Simon Bell, Jenni Ilomäki
Background: The rapid increase in prescribing and use of opioids for noncancer pain has coincided with an increase in opioid-related adverse drug events (ADEs). The objective of our study was to describe ADEs related to tapentadol and oxycodone/naloxone spontaneously reported to the Australian Therapeutic Goods Administration (TGA). Methods: Public case detail reports for tapentadol (September 2013-March 2017) and oxycodone/naloxone (April 2011-March 2017) were sourced from the TGA...
April 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29492247/likelihood-of-reporting-medication-errors-in-hospitalized-children-a-survey-of-nurses-and-physicians
#4
Rikke Mie Rishoej, Jesper Hallas, Lene Juel Kjeldsen, Henrik Thybo Christesen, Anna Birna Almarsdóttir
Background: Hospitalized children are at risk of medication errors (MEs) due to complex dosage calculations and preparations. Incident reporting systems may facilitate prevention of MEs but underreporting potentially undermines this system. We aimed to examine whether scenarios involving medications should be reported to a national mandatory incident reporting system and the likelihood of self- and peer-reporting these scenarios among paediatric nurses and physicians. Methods: Participants' reporting of MEs was explored through a questionnaire involving 20 medication scenarios...
March 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29492246/an-update-on-the-safety-of-current-therapies-for-alzheimer-s-disease-focus-on-rivastigmine
#5
REVIEW
Rita Khoury, Jayashree Rajamanickam, George T Grossberg
Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-receptor antagonist memantine. Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD. Although they share the same mode of action, they differ in terms of their pharmacologic characteristics and route of administration, which can impact their safety and tolerability profile...
March 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29492245/can-supporting-health-literacy-reduce-medication-related-harm-in-older-adults
#6
EDITORIAL
Nikesh Parekh, Khalid Ali, Kevin Davies, Chakravarthi Rajkumar
No abstract text is available yet for this article.
March 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29387338/polypills-for-the-secondary-prevention-of-cardiovascular-disease-effective-in-improving-adherence-but-are-they-safe
#7
REVIEW
Vanessa Selak, Ruth Webster
International guidelines recommend blood pressure-lowering therapy, statins and aspirin for people who have had a cardiovascular event but use of these medications is low, particularly for lower income countries. Clinical trials have demonstrated that combining these medications into a single pill or capsule (a 'polypill') improves adherence, systolic blood pressure and low density lipoprotein cholesterol compared with usual care in secondary prevention. Uptake of polypill-based care has been underwhelming, possibly due to safety concerns...
February 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29387337/interventions-to-reduce-medication-errors-in-neonatal-care-a-systematic-review
#8
REVIEW
Minh-Nha Rhylie Nguyen, Cassandra Mosel, Luke E Grzeskowiak
Background: Medication errors represent a significant but often preventable cause of morbidity and mortality in neonates. The objective of this systematic review was to determine the effectiveness of interventions to reduce neonatal medication errors. Methods: A systematic review was undertaken of all comparative and noncomparative studies published in any language, identified from searches of PubMed and EMBASE and reference-list checking. Eligible studies were those investigating the impact of any medication safety interventions aimed at reducing medication errors in neonates in the hospital setting...
February 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29387336/influence-of-stroke-and-bleeding-risk-on-prescribing-of-oral-anticoagulants-in-older-inpatients-has-the-availability-of-direct-oral-anticoagulants-changed-prescribing
#9
Nicholas Farinola, Gillian E Caughey, J Simon Bell, Sally Johns, Milka Hauta-Aho, Sepehr Shakib
Background: Little is known about changes in prescribing practices in Australia since the introduction of the direct oral anticoagulants (DOACs). Our objective was to examine if the availability of DOACs has coincided with a change in prescribing of oral anticoagulants in older hospital inpatients with regard to risk factors for stroke and bleeding. Methods: A prospective observational study was conducted between October 2012 and August 2015 of inpatients aged over 60 years initiated on an oral anticoagulant in a large metropolitan, tertiary referral, public teaching hospital in Australia...
February 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29387335/contemporary-utilization-of-antithrombotic-therapy-for-stroke-prevention-in-patients-with-atrial-fibrillation-an-audit-in-an-australian-hospital-setting
#10
Ekta Yogeshkumar Pandya, Elizabeth Anderson, Clara Chow, Yishen Wang, Beata Bajorek
Background: To document antithrombotic utilization in patients with nonvalvular atrial fibrillation (NVAF), particularly, recently approved NOACs (nonvitamin K antagonist oral anticoagulants) and warfarin; and identify factors predicting the use of NOACs versus warfarin. Methods: A retrospective audit was conducted in an Australian hospital. Data pertaining to inpatients diagnosed with atrial fibrillation (AF) admitted between January and December 2014 were extracted...
February 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318007/severe-haematuria-of-lower-urinary-tract-origin-with-low-dose-dabigatran-use-in-three-indian-elderly-patients-unresolved-issues-in-the-safety-of-novel-oral-anticoagulants
#11
Upinder Kaur, Sankha Shubhra Chakrabarti, Sukdev Manna, Indrajeet Singh Gambhir
Dabigatran is a newer oral direct thrombin inhibitor approved by the United States Food and Drug Administration and the European Medicines Agency (EMA). The proper dosage of the drug, the potential for adverse drug reactions and the nature of bleeds with use of this drug as with other novel oral anticoagulants (NOACs), in the elderly population are still areas of uncertainty. Despite the existence of a specific antibody, idarucizumab which is an antidote to dabigatran toxicity, management of dabigatran-induced bleeds is an undefined area especially in resource constrained settings...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318006/naloxone-dosage-for-opioid-reversal-current-evidence-and-clinical-implications
#12
REVIEW
Rachael Rzasa Lynn, J L Galinkin
Opioid-related mortality is a growing problem in the United States, and in 2015 there were over 33,000 opioid-related deaths. To combat this mortality trend, naloxone is increasingly being utilized in a pre-hospital setting by emergency personnel and prescribed to laypersons for out-of-hospital administration. With increased utilization of naloxone there has been a subsequent reduction in mortality following an opioid overdose. Reversal of opioid toxicity may precipitate an opioid-withdrawal syndrome. At the same time, there is a risk of inadequate response or re-narcotization after the administration of a single dose of naloxone in patients who have taken large doses or long-acting opioid formulations, as the duration of effect of naloxone is shorter than that of many opioid agonists...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318005/precision-medicine-does-ethnicity-information-complement-genotype-based-prescribing-decisions
#13
REVIEW
Rashmi R Shah, Andrea Gaedigk
Inter-ethnic differences in drug response are all too well known. These are underpinned by a number of factors, including pharmacogenetic differences across various ethnic populations. Precision medicine relies on genotype-based prescribing decisions with the aim of maximizing efficacy and mitigating the risks. When there is no access to genotyping tests, ethnicity is frequently regarded as a proxy of the patient's probable genotype on the basis of overall population-based frequency of genetic variations in the ethnic group the patient belongs to, with some variations being ethnicity-specific...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318004/poly-de-prescribing-to-treat-polypharmacy-efficacy-and-safety
#14
Doron Garfinkel
Background: The aim of this study was to evaluate efficacy and safety of poly-de-prescribing (PDP) based on the Garfinkel method in older people with polypharmacy. Methods: A longitudinal, prospective, nonrandomized study in Israel was carried out between 2009 and 2016. Comprehensive geriatric assessments were performed at home in people age ⩾66 years consuming ⩾6 prescription drugs. Exclusion criteria were life expectancy <6 months and a seeming unwillingness to cooperate (poor compliance)...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318003/incident-adverse-drug-reactions-in-geriatric-inpatients-a-multicentred-observational-study
#15
Amanda Lavan, Joseph Eustace, Darren Dahly, Evelyn Flanagan, Paul Gallagher, Shane Cullinane, Mirko Petrovic, Katrina Perehudoff, Adalsteinn Gudmondsson, Ólafur Samuelsson, Ástrós Sverrisdóttir, Antonio Cherubin, Frederica Dimitri, Joe Rimland, Alfonso Cruz-Jentoft, Manuel Vélez-Díaz-Pallarés, Isabel Lozano Montoya, Roy L Soiza, Selvarani Subbarayan, Denis O'Mahony
Background: Adverse drug reactions (ADRs) are common in older adults and frequently have serious clinical and economic consequences. This study was conducted as a feasibility study for a randomized control trial (RCT) that will investigate the efficacy of a software engine to optimize medications and reduce incident (in-hospital) ADRs. This study's objectives were to (i) establish current incident ADR rates across the six sites participating in the forthcoming RCT and (ii) assess whether incident ADRs are predictable...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318002/the-hope-hype-and-reality-of-big-data-for-pharmacovigilance
#16
EDITORIAL
Andrew Bate, Robert F Reynolds, Patrick Caubel
No abstract text is available yet for this article.
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29204267/tamsulosin-induced-diarrhea-a-case-report
#17
Arunkumar D Rana, Kinjal Dodiya, Manish J Barvaliya, Sameer Shah, Bhargav M Purohit, Chandrabhanu Rajkishor Tripathi
No abstract text is available yet for this article.
December 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29204266/pegloticase-in-gout-treatment-safety-issues-latest-evidence-and-clinical-considerations
#18
REVIEW
Allison Guttmann, Svetlana Krasnokutsky, Michael H Pillinger, Adey Berhanu
Gout is a common rheumatic condition, with increasing prevalence in recent decades. The mainstay of treatment for gout is oral urate-lowering therapy (ULT), typically with xanthine oxidase inhibitors (XOIs). Unfortunately, a proportion of patients have persistent gout that is refractory to ULT. Pegloticase, a recombinant pegylated uricase, has been approved by the US Food and Drug Administration for the treatment of refractory gout. However, concern has been raised regarding the risk of infusion reactions, which are now understood to be largely due to the development of antipegloticase antibodies...
December 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29204265/using-deep-learning-to-improve-medication-safety-the-untapped-potential-of-social-media
#19
EDITORIAL
Jiaheng Xie, Daniel Dajun Zeng, Zachary A Marcum
No abstract text is available yet for this article.
December 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29090085/assessing-and-predicting-drug-induced-anticholinergic-risks-an-integrated-computational-approach
#20
Dong Xu, Heather D Anderson, Aoxiang Tao, Katia L Hannah, Sunny A Linnebur, Robert J Valuck, Vaughn L Culbertson
BACKGROUND: Anticholinergic (AC) adverse drug events (ADEs) are caused by inhibition of muscarinic receptors as a result of designated or off-target drug-receptor interactions. In practice, AC toxicity is assessed primarily based on clinician experience. The goal of this study was to evaluate a novel concept of integrating big pharmacological and healthcare data to assess clinical AC toxicity risks. METHODS: AC toxicity scores (ATSs) were computed using drug-receptor inhibitions identified through pharmacological data screening...
November 2017: Therapeutic Advances in Drug Safety
journal
journal
43349
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"